Although significant advances in the treatment of diabetes in general and diabetic retinopathy specifically have made the disease more manageable, these benefits are only realized if patients have access to care. Read more: modernretina.com/view/social-fa…

Atsena Therapeutics, announced that the FDA has granted Orphan Drug Designation for ATSN-201 for the treatment of X-linked retinoschisis (XLRS). Read more: modernretina.com/view/atsena-th…

Margaret A. Chang, MD, MS, discussed her EURETINA presentation, “Patient Preference for the Port Delivery System With Ranibizumab vs Intravitreal Injections: Results From the Phase 3 Pagoda Trial in Patients With Diabetic Macular Oedema.” Read more: modernretina.com/view/euretina-…

Opthea Limited has made changes to the company’s executive leadership in its finance and commercial areas and has made notable hires in its biometrics, clinical operations, and market access departments. Read more: modernretina.com/view/opthea-ma…

4D Molecular Therapeutics has announced data based on the longest interim follow-up from Phase 1/2 PRISM clinical trial and 4FRONT Phase 3 study design. These results are a part of the company’s 4D-150 Wet AMD Development Day. Read more: modernretina.com/view/4dmt-shar…

Retina is a rapidly advancing field with promising research, technology, and treatment areas. Two stand out as particularly exciting: Gene therapy and technology! Read more: modernretina.com/view/the-futur…

The COVID-19 infection or vaccination may be associated with numerous ocular manifestations of which ophthalmologists should be aware, according to Nesrine Abroug, MD, and colleagues. Read more: modernretina.com/view/euretina-…

Ophthalmologists sought to predict the yearly growth rate of GA and to select the potentially faster-growing lesions from 2 eyes based on FAF, (NIR), and OCT. A deep learning algorithm predicted progression solely on the baseline OCT. Read more: modernretina.com/view/oct-based…

Veeral Sheth, MD, MBA, FASRS, FACS, explores the advancements in gene therapy for nAMD, focusing on the work of REGENXBIO, 4D Molecular Therapeutics (4DMT), and Adverum Biotechnologies. Read more: modernretina.com/view/the-curre…

ANI Pharmaceuticals Inc. announced the completion of its previously announced acquisition of Alimera Sciences Inc. Under the terms of the agreement, ANI acquired all outstanding shares of Alimera for $5.50 per share. Read more: modernretina.com/view/ani-pharm…

Atsena Therapeutics, announced that the FDA has granted Orphan Drug Designation for ATSN-201 for the treatment of X-linked retinoschisis (XLRS). Read more: modernretina.com/view/atsena-th…

Margaret A. Chang, MD, MS, discussed her EURETINA presentation, “Patient Preference for the Port Delivery System With Ranibizumab vs Intravitreal Injections: Results From the Phase 3 Pagoda Trial in Patients With Diabetic Macular Oedema.” Read more: modernretina.com/view/euretina-…

Opthea Limited has made changes to the company’s executive leadership in its finance and commercial areas and has made notable hires in its biometrics, clinical operations, and market access departments. Read more: modernretina.com/view/opthea-ma…

4D Molecular Therapeutics has announced data based on the longest interim follow-up from Phase 1/2 PRISM clinical trial and 4FRONT Phase 3 study design. These results are a part of the company’s 4D-150 Wet AMD Development Day. Read more: modernretina.com/view/4dmt-shar…

Alaa Din Abdin, MD, and colleagues reported that a “remarkable” reversible change occurred in the retinal microvessels after patients experienced acute decompensated heart failure (ADHF). Read more: modernretina.com/view/euretina-…

Oral gildeuretinol demonstrated a clinically meaningful reduction in the GA lesion growth rate at 24 months in the SAGA study. Read more: modernretina.com/view/alkeus-ph…

The COVID-19 infection or vaccination may be associated with numerous ocular manifestations of which ophthalmologists should be aware, according to Nesrine Abroug, MD, and colleagues. Read more: modernretina.com/view/euretina-…

Ophthalmologists sought to predict the yearly growth rate of GA and to select the potentially faster-growing lesions from 2 eyes based on FAF, (NIR), and OCT. A deep learning algorithm predicted progression solely on the baseline OCT. Read more: modernretina.com/view/oct-based…

Opthea has completed its drug substance process performance qualification (PPQ) campaign for sozinibercept. Read more: modernretina.com/view/opthea-co…

ANI Pharmaceuticals Inc. announced the completion of its previously announced acquisition of Alimera Sciences Inc. Under the terms of the agreement, ANI acquired all outstanding shares of Alimera for $5.50 per share. Read more: modernretina.com/view/ani-pharm…